Coverage: October 26–November 1, 2026
This week brought a suspension of DWAP affecting medical device submissions, approval of a VR exercise-support program, and a proposed reimbursement listing for devices used to manage pleural effusion and ascites. These seven developments from Japan and overseas highlight points for regulatory affairs and business development teams to consider.
1. PMDA suspends DWAP: different responses for new submissions and document replacements
On October 29, PMDA announced the suspension of its medical device web application platform, DWAP. Unauthorized access was detected between October 23 and 26, and work is underway to address vulnerabilities. At the time of the announcement, no information leakage, alteration or destruction of existing data had been identified. The date for resuming operations remained undecided.
PMDA directs applicants to the FD application software for preparing new approval applications and notifications. For replacement documents in applications or notifications already submitted, procedures will be announced once decided. Projects preparing their first submission therefore need to be handled differently from those awaiting document replacement after submission. When deadlines are approaching, teams should adjust their work plans in light of further PMDA notices and guidance from the relevant contact. PMDA announcement
2. FDA publishes draft guidance on electronic submission templates for IDE applications
FDA published draft guidance on an electronic submission template for Investigational Device Exemption (IDE) applications. The comment deadline is December 28.
The document is not yet final. Companies planning clinical investigations in the United States should review the direction of electronic submission requirements while distinguishing current procedures from potential future changes. FDA guidance
3. mediVR announces medical device approval for standalone software
On October 29, mediVR announced that “mediVR Kagura Feedback” received Japanese marketing approval as a Class II medical device on October 15. The program provides visual, auditory and tactile feedback for exercises in which users reach toward targets in a VR environment.
The approval covers standalone software, not hardware. For developers of VR-based medical devices, it offers a reference point when considering which parts of the equipment and program should fall within an application. However, even products using the same technology may follow different classifications and submission pathways depending on their intended use and functions. When examining a precedent, it is therefore important to consider not only the shared technology but also the scope of the approved product. mediVR announcement
4. PleurX reimbursement proposal evaluates the catheter and drainage device separately
Documents for the October 28 meeting of Japan’s Central Social Insurance Medical Council set out proposed reimbursement categories and prices for PleurX. The intended population is adults with treatment-resistant, recurrent and symptomatic pleural effusion or ascites. The catheter is proposed under category C2 at ¥53,600 and the drainage device under C1 at ¥5,040, with a planned listing date of December 1.
Even when products are used together in one treatment, individual components may be assessed under different categories and prices, as in this proposal. Medical device business plans should therefore consider not just the selling price of the overall system but also how each component is used and treated under reimbursement. These prices remain proposals; the formal notice and billing conditions need to be checked before incorporating them into plans. Council documents
5. Empatica announces an at-home Parkinson’s monitoring product
On October 28, Empatica announced WellPD, combining a wrist-worn device and an app to record Parkinson’s motor symptoms at home.
The company describes the product as already FDA-cleared and CE-marked. This is a product rollout announcement, not an announcement that new regulatory procedures were completed this week. Empatica announcement
6. RadNet announces an agreement to acquire teleradiology provider ONRAD
On October 26, RadNet announced a definitive agreement to acquire ONRAD, a teleradiology services provider. Consideration comprises $350 million in cash and five million RadNet shares, together with additional payments linked to performance conditions.
Completion is expected in early 2027, subject to regulatory approvals and other conditions. In diagnostic imaging, changes to business structures that include image-interpretation services merit attention alongside developments in equipment and software. RadNet announcement
7. GT Metabolic raises Series C funding to expand gastrointestinal anastomosis technology
GT Metabolic Solutions announced a Series C financing led by J.P. Morgan Life Sciences Private Capital. The company plans to advance commercialization of its magnetic compression technology for gastrointestinal anastomosis and expand into endoscopic and colorectal surgery applications.
For devices involving new procedures, development progress should be tracked separately from indications, clinical evaluation and implementation arrangements. This announcement concerns funding and business plans; it does not establish approval of new indications. Company announcement
This week’s summary
The DWAP suspension calls for responses tailored to the stage of submission; mediVR highlights the scope of the product included in an application; and PleurX illustrates component-level reimbursement assessment. To understand the implications for a particular product, announcements should be considered in the context of its intended use, development stage and submission status rather than applied directly without qualification.
MK Consulting supports medical device regulatory submissions and clinical evaluation. Contact us for assistance with planning the submission approach, identifying the necessary tests and evaluations, and preparing submission documents.